Response Biomedical To Present 2 Studies On Chest Pain

Armen Hareyan's picture

Chest Pain

Response Biomedical Corporation announced that it is presenting data from two international studies at the Tenth Congress of Chest Pain Centers - The Chest Pain Center - A Team Approach in ACS Care.


The studies, conducted in France and Italy, both concluded that the RAMP NT-proBNP assays evaluated performed equivalently to the local laboratory systems.

"Clinical Utility of the RAMP Whole Blood NT-proBNP Assay for the Exclusion of Acute Heart Failure" showcases data from a clinical trial conducted at the Laboratoire de Biochimie Generale et Specialsee, Hopital Civil, Strabourg, France. The aim of the study was to compare the RAMP point-of-care (POC) and laboratory based Dade Dimension RxL systems for measurement of NT-proBNP levels in patients suspected of having heart failure (HF). Clinical concordance analysis showed excellent clinical agreement between the RAMP and the Dimension RxL. The RAMP NT-proBNP whole blood assay was shown to be an accurate indicator that can be used to rule out acute HF in the trial's patient population, with results comparable to the Dimension RxL, laboratory analyzer. With results available in 15 minutes, the RAMP NT-proBNP Assay allows for rapid initiation of appropriate patient treatment.

"Evaluation of RAMP Whole Blood Analyzer for POC Troponin I (TnI) and NT-proBNP Testing" outlines data from a clinical trial conducted at the Laboratorio di Chimica Clinica ed Ematologia, Ospedale S. Bortolo, Vicenza, Italy. The study evaluated the performance of the RAMP POC whole blood tests for TnI and NT-proBNP for the accurate and rapid measurement of bio-markers to aid in the diagnosis of cardiovascular disease. Both RAMP assays showed strong correlation with the respective laboratory assays (NT-proBNP R=0.945 and 0.981 for TnI and NT-proBNP respectively). Clinical concordance between the RAMP POC and the laboratory systems was 87% for TnI and 97.6% for NT-proBNP.